American Century Companies Inc. Grows Position in Celldex Therapeutics, Inc. $CLDX

American Century Companies Inc. grew its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 24.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 779,985 shares of the biopharmaceutical company’s stock after acquiring an additional 154,664 shares during the quarter. American Century Companies Inc. owned 1.17% of Celldex Therapeutics worth $15,873,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of CLDX. Nisa Investment Advisors LLC grew its holdings in shares of Celldex Therapeutics by 171.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 881 shares in the last quarter. AlphaQuest LLC raised its stake in Celldex Therapeutics by 182.5% during the first quarter. AlphaQuest LLC now owns 12,112 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 7,825 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in Celldex Therapeutics during the first quarter valued at $265,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Celldex Therapeutics during the first quarter valued at $269,000. Finally, Police & Firemen s Retirement System of New Jersey grew its stake in shares of Celldex Therapeutics by 9.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 15,272 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 1,349 shares in the last quarter.

Celldex Therapeutics Price Performance

Shares of CLDX stock opened at $26.67 on Wednesday. The company has a market capitalization of $1.77 billion, a P/E ratio of -7.89 and a beta of 1.13. The company’s 50-day simple moving average is $25.92 and its two-hundred day simple moving average is $23.42. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $29.05.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 33.22%. On average, research analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. HC Wainwright decreased their target price on shares of Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating on the stock in a research report on Wednesday, August 20th. Citigroup reduced their price objective on Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating on the stock in a research note on Wednesday, August 20th. Mizuho initiated coverage on Celldex Therapeutics in a research report on Tuesday, October 21st. They set an “outperform” rating and a $48.00 price objective on the stock. Wells Fargo & Company dropped their target price on Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating for the company in a report on Wednesday, August 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $43.80.

Insider Buying and Selling at Celldex Therapeutics

In other Celldex Therapeutics news, insider Richard M. Wright sold 49,298 shares of the company’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $24.00, for a total value of $1,183,152.00. Following the completion of the sale, the insider directly owned 20,833 shares in the company, valued at approximately $499,992. This represents a 70.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.40% of the company’s stock.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.